1. Difference in cardiovascular treatment penetration in selected countries of Western and Central and Eastern Europe Petr Jelinek Corporate Marketing Department, Zentiva Group Prague, Cardionale 2010

2. Objective and definitions: To compare selected CEE countries and benchmark their treatment penetration with selected WE countries To show treatment consumptions and trends in the region Assumptions for this presentation CEE = Central and East Europe – CZ, SK, PL, HU, RO, BG, LT, LV, EE and RU, UA, TR WE = West Europe – France, U.K., Germany, Italy, Portugal, Spain SU = Standard Units = tablets Treatment penetration criterion = In pharmacy realized prescriptions drug consumption No. of treated patients

3. Dyslipidemia treatment

4. Market Analysis in CEE Dyslipidemia MARKET First Generics

5. Market Analysis in CEE STATINs MARKET First Generics Price per tablet in EUR

6. Treatment penetration development: Statins

7. Treatment penetration: all dyslipidemics* * incl. all dyslipidemic treatments classes as statin, fibrates and other dyslipidemics 6 WE Average

8. Treatment penetration: Statins

9. Treatment penetration: Fibrates

10. Market Analysis in CEE STATINs MARKET Most of Gx from 2001 Most of Gx from 2004 Gx 2010

11. Market Analysis in CEE STATINs MARKET Simva generics from 2003

12. Market Analysis Average statin dose in mg CEE vs. WE 24,9 21,4 14,1 8,9 20,6

13. Treatment penetration development: Statins

14. Antihypertension treatment

15. Market Analysis WE ANTIHYPERTENSIVES MARKET

16. Market Analysis WE ANTIHYPERTENSIVES MARKET SALES MS in %

17. Market Analysis CEE &TR & CIS ANTIHYPERTENSIVES MARKET

18. %

19. Treatment penetration: Hypertension* * incl. all antihypertension treatments classes as ACEI,CCB, Betablockers, diuretics, Sartans and others 6 WE Average Above average

20. Treatment penetration development: ACEI plain + combos Enalapril has still leading position among ACEI PRESENTATION / DATE

21. Treatment penetration: Calcium Chanel Blockers PRESENTATION / DATE

22. Treatment penetration: BetaBlockers

23. PRESENTATION / DATE Treatment penetration: Diuretics

24. PRESENTATION / DATE Treatment penetration development: Sartans

25. Market Analysis in CEE SARTANs MARKET Gx since 2003 - 2006

26. Treatment penetration development: Hypertension* * incl. all antihypertension treatments classes as ACEI,CCB, Betablockers, diuretics, Sartans and others

27. Antiagregans treatment

28. Market Analysis in CEE Low dose ASA Market

29. Clopidogrel Treatment penetration

30. Market Analysis in CEE Clopidogrel Market

31. First Generics Sec. Gx wave

32. Differences in dyslipidemia treatment penetration in selected countries of Western and Central and Eastern Europe Conclusions: In spite of constantly improving treatment penetration in CEE, there are significant differences among countries of the CEE region and WE and also among CEE as such The most comparable situation is in hypertension treatment, but differences still persist in penetration of modern treatment classes such as sartans There are significant differences between CEE and WE in dyslipidemia treatment penetration in most countries, mainly in statin class Usage of higher dose of statins is in CEE higher then in WE Low dose ASA is popular in the CEE region but for modern antiagregans treatment penetration (clopidogrel) the difference is the highest

33. Than you for your attention !